GNGT2: Guanine Nucleotide Binding Protein Gamma Transducing Activity Polypeptide 2

Target Name: GNGT2

NCBI ID: G2793

GNGT2

GNGT2: Guanine Nucleotide Binding Protein Gamma Transducing Activity Polypeptide 2

GNGT2 (Guanine Nucleotide Binding Protein Gamma Transducing Activity Polypeptide 2) is a protein that is expressed in various tissues and cells in the human body. It is a member of the GNGT family of proteins, which are known for their ability to interact with guanine nucleotides, which are the genetic units of DNA. GNGT2 is unique, however, in its ability to transduce this interaction into a response that can be used as a drug target or biomarker.

The GNGT2 protein is found in a variety of tissues, including the brain, heart, and kidneys. It is also expressed in various cell types, including muscle cells, nerve cells, and epithelial cells. GNGT2 is typically expressed at low levels, but it can be easily activated by guanine nucleotides. When GNGT2 is activated, it undergoes a conformational change that allows it to bind to guanine nucleotides. This interaction between GNGT2 and guanine nucleotides is the foundation of GNGT2's transducing activity.

GNGT2's transducing activity is regulated by various factors, including guanine nucleotide levels, DNA binding, and protein-protein interactions. These factors can all affect the strength and specificity of GNGT2's interaction with guanine nucleotides. Understanding how these factors influence GNGT2's transducing activity is an important step in the development of new drugs or biomarkers.

One of the potential benefits of GNGT2 as a drug target is its ability to modulate gene expression. GNGT2 has been shown to interact with various transcription factors, including NF-kappa-B, AP-1, and STAT3. This interaction allows GNGT2 to influence the activity of these transcription factors and, in turn, the expression of genes that are regulated by these factors. This modulation of gene expression can lead to a wide range of potential therapeutic applications, including the regulation of inflammation, stress response, and cellular processes that are involved in aging and disease.

Another potential application of GNGT2 as a drug target is its ability to serve as a biomarker for various diseases. GNGT2 has been shown to be expressed in a variety of disease-related tissues and cells, including cancer, neurodegenerative diseases, and autoimmune diseases. By using GNGT2 as a biomarker for these diseases, researchers can potentially develop new diagnostic tests or therapies. For example, if GNGT2 is expressed in a patient with cancer, a diagnostic test that measures the level of GNGT2 in the patient's tissue could be used to confirm the diagnosis. Similarly, if a patient has neurodegenerative diseases, a diagnostic test that measures the level of GNGT2 in the patient's brain could be used to monitor the effectiveness of a new treatment.

In addition to its potential as a drug target or biomarker, GNGT2 is also of interest to researchers because of its unique biochemical properties. GNGT2 is a member of the GNGT family of proteins, which are known for their ability to interact with guanine nucleotides. This interaction allows GNGT2 to undergo a conformational change that allows it to bind to guanine nucleotides. This conformational change is thought to be the result of a specific interaction between GNGT2's amino acid residues and the guanine nucleotides.

Research into the mechanisms of GNGT2's interaction with guanine nucleotides is an important step in the understanding of this protein's function. This research can also provide insights into the broader biochemical mechanisms that are involved in the regulation of gene expression and the development of diseases.

Protein Name: G Protein Subunit Gamma Transducin 2

Functions: Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction

The "GNGT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNGT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets